Financial Contrast: Pulse Biosciences (PLSE) and Dexcom (DXCM)

Pulse Biosciences (NASDAQ: PLSE) and Dexcom (NASDAQ:DXCM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Pulse Biosciences and Dexcom, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 0 0 0 0 N/A
Dexcom 2 5 12 0 2.53

Dexcom has a consensus price target of $74.50, indicating a potential downside of 22.19%. Given Dexcom’s higher possible upside, analysts clearly believe Dexcom is more favorable than Pulse Biosciences.

Risk & Volatility

Pulse Biosciences has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Dexcom has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.

Institutional and Insider Ownership

9.0% of Pulse Biosciences shares are owned by institutional investors. 39.3% of Pulse Biosciences shares are owned by insiders. Comparatively, 1.8% of Dexcom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Pulse Biosciences and Dexcom’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulse Biosciences N/A N/A -$25.56 million N/A N/A
Dexcom $718.50 million 11.74 -$50.20 million ($0.58) -165.09

Pulse Biosciences has higher earnings, but lower revenue than Dexcom.

Profitability

This table compares Pulse Biosciences and Dexcom’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences N/A -77.03% -70.27%
Dexcom -4.30% -9.32% -4.28%

About Pulse Biosciences

Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply